SultoprideSultopride
MedChemExpress (MCE)
HY-42849
53583-79-2
LIN-1418
Please store the product under the recommended conditions in the Certificate of Analysis.
Room temperature in continental US
may vary elsewhere.
Sultopride (LIN-1418) is a selective antagonist of dopamine D2 receptor.
Sultopride (LIN-1418) is a selective antagonist of dopamine D2 receptor. DOPAC and HVA levels in the striatum, the nucleus accumbens and the medial prefrontal cortex are higher in the rats treated with Sultopride and sulpiride than those of the controls. In the striatum, DOPAC and HVA levels are higher in the Sultopride-treated rats than the sulpiride-treated rats (p[1].
Thirty-six male Sprague-Dawley rats weighing 180 to 220 g are used in this study. The rats are divided into three groups of 6 each. One group is intraperitoneally injected with Sultopride (100 mg/kg body weight), the second group with sulphide (100 mg/kg body weight), and the third group with normal saline. One hundred minutes after the initial treatments, apomorphine (0.1 mg/kg body weight, dissolved in saline ad libitum) is administered subcutaneously to the three groups, and 20 minutes later the rats are sacrificed. The third group serves as controls[1].
Dopamine D2 receptor[1] In Vivo Sultopride (LIN-1418) is a selective antagonist of dopamine D2 receptor. DOPAC and HVA levels in the striatum, the nucleus accumbens and the medial prefrontal cortex are higher in the rats treated with Sultopride and sulpiride than those of the controls. In the striatum, DOPAC and HVA levels are higher in the Sultopride-treated rats than the sulpiride-treated rats (p[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| | | |
| | | | | |
[1]. Moriuchi K, et al. Differences in effects of sultopride and sulpiride on dopamine turnover in rat brain. Neurochem Res. 1995 Jan
20(1):95-9. [Content Brief]